Table I.
Patient Characteristics
| HDT-ASCT n=22 | Allo-HCT n=22 | |
|---|---|---|
| Median age, years (range) | 51 (34–71) | 56 (34–69) |
| Median number of previous lines of therapy (range) |
2 (2–4) | 3 (2–5) |
| Median time from diagnosis to transplant consolidation, months (range) |
35 (19–134) | 45 (19–362) |
| Chemosensitive | 21/22 (95%) | 19/22 (86%) |
| CR | 10 (all FDG-PET(−)) | 9 (6/7 FDG-PET(−)) |
| PR | 11 (5/9 FDG-PET(−)) | 10 (5/10 FDG-PET(−)) |
| Clinical Stage at Rel/Ref | ||
| 2–3 | 12 | 6 |
| 4 | 10 | 16 |
| Bone Marrow Involved at Rel/Ref | ||
| yes | 8 | 16 |
| no | 12 | 6 |
| sFLIPI | ||
| ≤ 2 | 10 | 9 |
| > 2 | 9 | 7 |
| Median remission duration prior to pre- transplant re-induction therapy, months (range) |
11.5 (0*–31) | 6 (0*–15) |
| Remission duration ≤ 12 months from pre- transplant re-induction therapy |
12/22 (55%) | 21/22 (95%) |
*
chemorefractory disease;
allo-HCT, allogeneic hematopoietic cell transplantation; CR, complete remission; FDG-PET, 18F-fludeoxyglucose positron emission tomography; HDT-ASCT, high-dose therapy and autologous stem cell transplantation; PR, partial remission; ref, refractory; rel, relapsed; sFLIPI, secondary follicular lymphoma international prognostic index